Huafu Securities released a research report on April 23 stating that it gave Shengnuo Biotech (688117.SH) a purchase rating, and the target price was 35.7 yuan. The main reasons for the rating include: 1) incident: the company released the 2023 annual report and the 2024 quarterly report; 2) the 2023 performance grew steadily, and the volume of the pharmaceutical+pharmaceutical research business increased significantly; 3) the continuous expansion of API production capacity is expected to drive the company's performance acceleration. (Mainichi Keizai Shimbun)
华福证券4月23日发布研报称，给予圣诺生物（688117.SH）买入评级，目标价格为35.7元。评级理由主要包括：1）事件：公司发布2023年度报告及2024年一季报；2）2023年业绩稳健增长，制剂+药学研究业务放量明显；3）原料药产能持续扩张，有望带动公司业绩提速。（每日经济新闻）
Huafu Securities released a research report on April 23 stating that it gave Shengnuo Biotech (688117.SH) a purchase rating, and the target price was 35.7 yuan. The main reasons for the rating include: 1) incident: the company released the 2023 annual rep
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.